Secondary analysis of RTOG 0247 demonstrates favorable OS rates for rectal cancer patients

Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a study published in the January 1, 2015 issue of the International Journal of Radiation Oncology * Biology * Physics, the official scientific journal of the American Society for Radiation Oncology. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *